NASDAQ: CUE
Cue Biopharma Inc Stock Ownership - Who owns Cue Biopharma?

Insider buying vs selling

Have Cue Biopharma Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Pasha SarrafDirector2025-12-304,229$0.31
$1.31kBuy
Pasha SarrafDirector2025-12-3077,148$0.30
$23.14kBuy
Pasha SarrafDirector2025-12-3086,947$0.32
$27.56kBuy
Pasha SarrafDirector2025-12-3078,116$0.31
$24.29kBuy
Pasha SarrafDirector2025-12-3077,417$0.30
$23.38kBuy

1 of 1

CUE insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when CUE insiders and whales buy or sell their stock.

CUE Shareholders

What type of owners hold Cue Biopharma Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Bleichroeder LP6.98%6,819,164$4.13MInstitution
Gc Wealth Management Ria LLC4.74%4,631,644$2.81MInstitution
Vanguard Group Inc3.09%3,014,034$1.83MInstitution
Lion Point Capital LP2.26%2,202,854$1.33MInstitution
Cameron Gray1.31%1,283,249$777.65kInsider
Aaron Gl Fletcher1.14%1,113,867$675.00kInsider
Michael J. Fox1.13%1,100,000$666.60kInsider
Geode Capital Management LLC0.82%803,291$486.79kInstitution
Christopher A. Marlett0.79%768,503$465.71kInsider
Boothbay Fund Management LLC0.72%704,297$426.80kInstitution

1 of 3

CUE vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CUE22.31%6.13%Net Buying
ACET29.20%70.80%Net BuyingNet Buying
ATYR55.92%15.71%Net BuyingNet Selling
CSBR1.95%98.05%Net Buying
INO47.80%45.03%Net SellingNet Selling

Cue Biopharma Stock Ownership FAQ

Who owns Cue Biopharma?

Cue Biopharma (NASDAQ: CUE) is owned by 22.31% institutional shareholders, 6.13% Cue Biopharma insiders, and 71.56% retail investors. Cameron Gray is the largest individual Cue Biopharma shareholder, owning 1.28M shares representing 1.31% of the company. Cameron Gray's Cue Biopharma shares are currently valued at $1.09M.

If you're new to stock investing, here's how to buy Cue Biopharma stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.